Managing Immune-Related Adverse Events in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Paul Bunn, MD
Managing High-Risk Subgroups in Metastatic NSCLC
Melina Marmarelis, MD
Deepa Rangachari, MD
Communicating Pathologic Response Results in Resectable NSCLC
Alexander Spira, MD, PhD, FACP
Robert Merritt, MD
Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Laura Alder, MD
Christine Bestvina, MD
Emerging Therapeutic Strategies in Metastatic NSCLC
Brian P. McDonough, MD, FAAFP
Urs Weber, MD
Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
Hallie Blevins, PhD
Marlene Mimi Maeusli, PhD.
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Steve Jackson, PharmD
Raghava Reddy Induru, MD
Optimizing Multidisciplinary Care in Perioperative NSCLC
David Tom Cooke, MD, FACS
Joshua Reuss, MD
Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Choosing the Right Treatment in ALK and ROS1-Positive NSCLC
Managing Brain Metastases in ALK+ NSCLC
Perioperative Immunotherapy Strategies in Resectable NSCLC Care
Martin Dietrich, MD, PhD
Early Detection Shapes Outcomes in Post-Transplant Lung Cancer
The Epigenetics of Lung Cancer Dormancy and Relapse
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.